MGI, a company committed to being a world-leading life science innovator, has announced a partnership with Nalagenetics (NALA) to co-develop low coverage whole genome sequencing for risk prediction and population genomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI sequencing devices and products.

The collaboration aims to use NALA's Clinical Decision Support, a software medical device, to be able to analyze whole genome sequencing data sets generated by MGI's DNBSEQ™ sequencing platform and generate clinical-grade reports for pharmacogenomics and polygenic risk scores. Although NGS has been known to be an effective way to capture a large amount of genomic information to guide and tailor clinical management and treatment, NGS workflows are complicated and not trivial to adopt in clinical settings. NALA is dedicated itself to helping implement clinical genetic testing in Southeast Asia. It has strong expertise in pharmacogenetics, population genomics, assay development, and AI-linked genetics analysis for pharmacological phenotypes and risk prediction.